Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

Benchmarking of Human Dose Prediction for Inhaled Medicines from Preclinical In Vivo Data.

Ericsson T, Fridén M, Kärrman-Mårdh C, Dainty I, Grime K.

Pharm Res. 2017 Dec;34(12):2557-2567. doi: 10.1007/s11095-017-2218-z. Epub 2017 Jul 6.

PMID:
28685298
2.

Pharmacological characterization of AZD5069, a slowly reversible CXC chemokine receptor 2 antagonist.

Nicholls DJ, Wiley K, Dainty I, MacIntosh F, Phillips C, Gaw A, Mårdh CK.

J Pharmacol Exp Ther. 2015 May;353(2):340-50. doi: 10.1124/jpet.114.221358. Epub 2015 Mar 3.

PMID:
25736418
3.

Biochemical and pharmacological characterization of AZD1981, an orally available selective DP2 antagonist in clinical development for asthma.

Schmidt JA, Bell FM, Akam E, Marshall C, Dainty IA, Heinemann A, Dougall IG, Bonnert RV, Sargent CA.

Br J Pharmacol. 2013 Apr;168(7):1626-38. doi: 10.1111/bph.12053.

4.

From libraries to candidate: the discovery of new ultra long-acting dibasic β₂-adrenoceptor agonists.

Alcaraz L, Bailey A, Cadogan E, Connolly S, Jewell R, Jordan S, Kindon N, Lister A, Lawson M, Mullen A, Dainty I, Nicholls D, Paine S, Pairaudeau G, Stocks MJ, Thorne P, Young A.

Bioorg Med Chem Lett. 2012 Jan 1;22(1):689-95. doi: 10.1016/j.bmcl.2011.10.049. Epub 2011 Oct 20.

PMID:
22079756
5.

Formoterol and salmeterol induce a similar degree of β2-adrenoceptor tolerance in human small airways but via different mechanisms.

Cooper PR, Kurten RC, Zhang J, Nicholls DJ, Dainty IA, Panettieri RA.

Br J Pharmacol. 2011 Jun;163(3):521-32. doi: 10.1111/j.1476-5381.2011.01257.x.

6.

Agonist-specific patterns of beta 2-adrenoceptor responses in human airway cells during prolonged exposure.

Düringer C, Grundström G, Gürcan E, Dainty IA, Lawson M, Korn SH, Jerre A, Håkansson HF, Wieslander E, Fredriksson K, Sköld CM, Löfdahl M, Löfdahl CG, Nicholls DJ, Silberstein DS.

Br J Pharmacol. 2009 Sep;158(1):169-79. doi: 10.1111/j.1476-5381.2009.00262.x. Epub 2009 Jun 22.

7.

Ca(2+) signalling by recombinant human CXCR2 chemokine receptors is potentiated by P2Y nucleotide receptors in HEK cells.

Werry TD, Christie MI, Dainty IA, Wilkinson GF, Willars GB.

Br J Pharmacol. 2002 Mar;135(5):1199-208.

8.

P2Y1-receptors in human platelets which are pharmacologically distinct from P2Y(ADP)-receptors.

Fagura MS, Dainty IA, McKay GD, Kirk IP, Humphries RG, Robertson MJ, Dougall IG, Leff P.

Br J Pharmacol. 1998 May;124(1):157-64.

9.

Cloning and characterisation of a bovine P2Y receptor.

Henderson DJ, Elliot DG, Smith GM, Webb TE, Dainty IA.

Biochem Biophys Res Commun. 1995 Jul 17;212(2):648-56.

PMID:
7626079
10.
11.

Further subclassification of ATP receptors based on agonist studies.

O'Connor SE, Dainty IA, Leff P.

Trends Pharmacol Sci. 1991 Apr;12(4):137-41. Review.

PMID:
2063479
13.

The influence of the initial stretch and the agonist-induced tone on the effect of basal and stimulated release of EDRF.

Dainty IA, McGrath JC, Spedding M, Templeton AG.

Br J Pharmacol. 1990 Aug;100(4):767-73.

14.

Interactions of palmitoyl carnitine with the endothelium in rat aorta.

Dainty IA, Bigaud M, McGrath JC, Spedding M.

Br J Pharmacol. 1990 Jun;100(2):241-6.

15.

Errors in agonist affinity estimation: do they and should they occur in isolated tissue experiments?

Leff P, Dougall IG, Harper DH, Dainty IA.

Trends Pharmacol Sci. 1990 Feb;11(2):64-7. Review.

PMID:
2180161
16.

The interaction of methoctramine and himbacine at atrial, smooth muscle and endothelial muscarinic receptors in vitro.

Eglen RM, Montgomery WW, Dainty IA, Dubuque LK, Whiting RL.

Br J Pharmacol. 1988 Dec;95(4):1031-8.

Supplemental Content

Loading ...
Support Center